Regensight is the world’s first Company introducing theranostics for the treatment of eye diseases
(therapy guided by imaging diagnostics) is a combination of therapy and diagnostics; it is a revolutionary paradigm of personalized and precision medicine, which makes use of light activated image-guided drug therapy to achieve the best outcome in the treatment of visual disorders.
Regensight has developed a theranostic surgical platform for the treatment of the most frequent visual disorders in young people, such as myopia and keratoconus, and in the elderly, such as presbyopia.
The Regensight platform assists the surgeon in tailoring the precise therapeutic UV-A energy dose onto patterned biochormophore delivered across the cornea.
We aim at elevating current surgical standards for the correction of visual disorders with a completely free incision treatment approach.
THERANOSTICS is an intelligent surgical therapy, which is driven by real time assessment of treatment response.
The platform is the world’s first surgical product using the IoMT (Internet of Medical Things) technology providing remote control for predictive maintenance, improving clinical research data collection and product improvement.
The Platform holds “fleet’s learning” ability, thus making Regensight as the world’s first biomedical manufacturer of an adaptive surgical platform.
THERANOSTICS is an intelligent surgical therapy, which is driven by real time image analysis of the eye under treatment.
Regensight is developing the modules of the theranostics platform, which include a theranostic UV-A medical device and a delivery device for personalized delivery of a biochromophore ophthalmic formulation into the cornea
We are working to offer eye surgeons a new, incision-free and risk-free, approach leading to precise and effective correction of the most frequent visual disorders in young and old people.
Our Short-Term Plan is focused on introducing theranostics for developing new treatment options for improving vision in keratoconus patients.
Our Mid-Term Plan is focused on developing revolutionary treatment options for people with low-grade myopia and presbyopia.
Our approved products
Currently, Regensight manufactures two CE marked medical devices for the indication of use of treating keratoconus and corneal ectasia with corneal cross-linking procedures. Learn More
Our aim is to validate theranostics for the correction of visual disorders
Learn more about ongoing, Regensight-promoted clinical trials below.
What are visual disorders?
Visual disorders, or refractive errors, are the most frequent causes of visual impairment worldwide. They can be caused by optical distortions (aberrations) of the eye or by a change in the axial length of the eye or by a decreased function of the intraocular muscles.The main refractive disorders causing visual impairment are:
is the primary cause of corneal transplantation in young people worldwide.
caused by longer eye axial length. It is the primary cause of visual impairment in young people.
caused by a decrease in accommodation. It is the primary cause of visual impairment in the elderly.
Limits of current medical technologies
Current surgical treatments of myopia, such as laser correction, although effective, have known problems, such as physical pain and the risk of infection and corneal scarring. In addition, laser correction of myopia is contraindicated in at least one third of people, who would like to undergo surgery, because the cornea is thin or because they have keratoconus.
Until today there is no effective and safe surgical solution for the most frequent visual disorder in the elderly, such as presbyopia, which affects two billion people worldwide!
Corneal cross-linking with riboflavin and UV-A light can be effective in halting keratoconus progression only if the corneal epithelium is removed; however, the epithelium removal has 15% rate of complications and the procedure does not improve visual acuity, which remains low due to the corneal distortion.
Current limits of riboflavin/UV-A corneal cross-linking
Efficacy of corneal cross-linking, intended as stabilization of disease progression, is highly variable (median of 70%) using the standard protocol (i.e., the cornea is de-epithelialized). Treatment effcacy is significantly lower with transepithelial protocols (i.e., the ccorneal epithelium is not removed). These factors forces eye surgeons to prefer the standard protocol, which, however, has high complication rates (incidence: 15%).
Current UV-A medical devices for the treatment of keratoconus have several technical limits:
The first evidences on efficacy of the Regensight platform for the treatment of keratoconus have been published in three prestigious high impact factor scientific journals:
Lombardo G, Bernava GM, Serrao S, M, Roszkowska AM, Lombardo M. Predicting corneal cross-linking efficacy with real-time assessment of corneal riboflavin concentration.
J Cataract Refract Surg 2023; 49(6): 635-641.
Roszkowska AM et al. A randomized clinical trial assessing theranostic-guided corneal cross-linking for treating keratoconus: the ARGO Protocol.
Int Ophthalmology 2022 Dec; E-pub ahead of print.
Lombardo G, Bernava GM, Serrao S, Lombardo M. Theranostic-guided corneal cross linking: pre-clinical evidence on a new treatment paradigm for keratoconus.
J Biophotonics 2022; 15(12):e202200218.
Lombardo G et al. Non-invasive optical method for real-time assessment of intracorneal riboflavin concentration and efficacy of corneal cross-linking.
J Biophotonics 2018;11(7):e201800028.
Lombardo M, Lombardo G. Non-invasive and real time assessment of riboflavin consumption in standard and accelerated corneal cross-linking.
J Cataract Refract Surg 2019; 45(1):80-86.
Lombardo G et al. Comparison between standard and transepithelial corneal cross-linking using a theranostic UV-A device.
Graefe’s Arch Clin Exp Ophthalmol 2020; 258(4): 829-834.
Lombardo M, Lombardo G.
Grand Round Stanford
Lombardo M, Lombardo G.
Grand Round UCL